In the most recent trading session, Eli Lilly (LLY) closed at $771.75, indicating a -3.45% shift from the previous trading day.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly (LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on ...

Alright, listen to me. This one is one that everyone’s going to give up on. Then one day, it’s going to be up 300, I’m not ...

GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes, researchers reported in San Francisco at ENDO 2025, the ...

President Donald Trump is keeping up the pace with seemingly a new tariff development every day. This time, he flagged that ...

Eli Lilly and Company (NYSE: LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the ...

The Eli Lilly and Company Foundation awarded a multi-year grant of up to $5.5 million to the Indianapolis Public Schools (IPS ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Connecticut passed a new law last week in an effort to lower its spending on weight-loss drugs for its state insurance ...

A new $5.5 million grant will fund STEM programs and career pathways for IPS middle and high school students starting at ...

Illustrating its confidence in its proprietary products, the Southern California company has announced an ambitious plan to ...